Wach Johannes, Hamed Motaz, Lampmann Tim, Güresir Ági, Schmeel Frederic Carsten, Becker Albert J, Herrlinger Ulrich, Vatter Hartmut, Güresir Erdem
Department of Neurosurgery, University Hospital Bonn, Bonn, Germany.
Department of Neuroradiology, University Hospital Bonn, Bonn, Germany.
Front Oncol. 2022 Aug 26;12:966581. doi: 10.3389/fonc.2022.966581. eCollection 2022.
MIB-1 index is an important predictor of meningioma progression. However, MIB-1 index is not available in the preoperative tailored medical decision-making process. A preoperative scoring sheet independently estimating MIB-1 indices in spinal meningioma (SM) patients has not been investigated so far.
Between 2000 and 2020, 128 patients with clinical data, tumor imaging data, inflammatory laboratory (plasma fibrinogen, serum C-reactive protein) data, and neuropathological reports (MIB-1, mitotic count, CD68 staining) underwent surgery for spinal WHO grade 1 and 2 meningioma.
An optimal MIB-1 index cut-off value (≥5/<5) predicting recurrence was calculated by ROC curve analysis (AUC: 0.83; 95%CI: 0.71-0.96). An increased MIB-1 index (≥5%) was observed in 55 patients (43.0%) and multivariable analysis revealed significant associations with baseline Modified McCormick Scale ≥2, age ≥65, and absence of calcification. A four-point scoring sheet (MAC-Spinal Meningioma) based on odified McCormick, ge, and alcification facilitates prediction of the MIB-1 index (sensitivity 71.1%, specificity 60.0%). Among those patients with a preoperative MAC-Meningioma Score ≥3, the probability of a MIB-1 index ≥5% was 81.3%.
This novel score (MAC-Spinal Meningioma) supports the preoperative estimation of an increased MIB-1 index, which might support preoperative patient-surgeon consultation, surgical decision making and enable a tailored follow-up schedule or an individual watch-and-wait strategy.
MIB-1指数是脑膜瘤进展的重要预测指标。然而,MIB-1指数在术前个性化医疗决策过程中无法获取。目前尚未对术前独立评估脊髓脑膜瘤(SM)患者MIB-1指数的评分表进行研究。
2000年至2020年间,128例具有临床数据、肿瘤影像数据、炎症实验室(血浆纤维蛋白原、血清C反应蛋白)数据以及神经病理学报告(MIB-1、有丝分裂计数、CD68染色)的患者接受了WHO 1级和2级脊髓脑膜瘤手术。
通过ROC曲线分析计算出预测复发的最佳MIB-1指数临界值(≥5/<5)(AUC:0.83;95%CI:0.71-0.96)。55例患者(43.0%)观察到MIB-1指数升高(≥5%),多变量分析显示与基线改良麦考密克量表≥2、年龄≥65岁以及无钙化显著相关。基于改良麦考密克量表、年龄和钙化情况的四分评分表(MAC-脊髓脑膜瘤)有助于预测MIB-1指数(敏感性71.1%,特异性60.0%)。在术前MAC-脑膜瘤评分≥3的患者中,MIB-1指数≥5%的概率为81.3%。
这种新的评分表(MAC-脊髓脑膜瘤)支持术前对升高的MIB-1指数进行评估,这可能有助于术前医患咨询、手术决策,并制定个性化的随访计划或个体化的观察等待策略。